C V Ly1, L Koenig2, J Christensen2, B Gordon2,3, H Beaumont1, S Dahiya4, J Chen4, Y Su5, B Nelson1, J Jockel-Balsarotti1, C Drain1, G Jerome1, J C Morris1,3, A M Fagan1,3,6, M B Harms7, T L S Benzinger2,3,8, T M Miller1,6, B M Ances1,2,3,6. 1. Department of Neurology, Washington University, Saint Louis, MO, USA. 2. Department of Radiology, Washington University, Saint Louis, MO, USA. 3. Knight Alzheimer's Disease Research Center, Washington University, Saint Louis, MO, USA. 4. Department of Pathology and Immunology, Washington University, Saint Louis, MO, USA. 5. Banner Alzheimer's Institute, Phoenix, AZ, USA. 6. Hope Center for Neurological Disorders, Washington University, Saint Louis, MO, USA. 7. Department of Neurology, Columbia University, New York, NY, USA. 8. Department of Neurosurgery, Washington University, Saint Louis, MO, USA.
Abstract
BACKGROUND AND PURPOSE: AV-1451 (18 F-AV-1451, flortaucipir) positron emission tomography was performed in C9orf72 expansion carriers to assess tau accumulation and disease manifestation. METHODS: Nine clinically characterized C9orf72 expansion carriers and 18 age- and gender- matched cognitively normal individuals were psychometrically evaluated and underwent tau positron emission tomography imaging. The regional AV-1451 standard uptake value ratios from multiple brain regions were analyzed. Spearman correlation was performed to relate the AV-1451 standard uptake value ratio to clinical, psychometric and cerebrospinal fluid measures. RESULTS: C9orf72 expansion carriers had increased AV-1451 binding in the entorhinal cortex compared to controls. Primary age-related tauopathy was observed postmortem in one patient. AV-1451 uptake did not correlate with clinical severity, disease duration, psychometric performance or cerebrospinal fluid markers. CONCLUSION: C9orf72 expansion carriers exhibited increased AV-1451 uptake in entorhinal cortex compared to cognitively normal controls, suggesting a propensity for primary age-related tauopathy. However, AV-1451 accumulation was not associated with psychometric performance in our cohort.
BACKGROUND AND PURPOSE:AV-1451 (18 F-AV-1451, flortaucipir) positron emission tomography was performed in C9orf72 expansion carriers to assess tau accumulation and disease manifestation. METHODS: Nine clinically characterized C9orf72 expansion carriers and 18 age- and gender- matched cognitively normal individuals were psychometrically evaluated and underwent tau positron emission tomography imaging. The regional AV-1451 standard uptake value ratios from multiple brain regions were analyzed. Spearman correlation was performed to relate the AV-1451 standard uptake value ratio to clinical, psychometric and cerebrospinal fluid measures. RESULTS:C9orf72 expansion carriers had increased AV-1451 binding in the entorhinal cortex compared to controls. Primary age-related tauopathy was observed postmortem in one patient. AV-1451 uptake did not correlate with clinical severity, disease duration, psychometric performance or cerebrospinal fluid markers. CONCLUSION:C9orf72 expansion carriers exhibited increased AV-1451 uptake in entorhinal cortex compared to cognitively normal controls, suggesting a propensity for primary age-related tauopathy. However, AV-1451 accumulation was not associated with psychometric performance in our cohort.
Authors: Andrei G Vlassenko; Lena McCue; Mateusz S Jasielec; Yi Su; Brian A Gordon; Chengjie Xiong; David M Holtzman; Tammie L S Benzinger; John C Morris; Anne M Fagan Journal: Ann Neurol Date: 2016-07-25 Impact factor: 10.422
Authors: David T Chien; Shadfar Bahri; A Katrin Szardenings; Joseph C Walsh; Fanrong Mu; Min-Ying Su; William R Shankle; Arkadij Elizarov; Hartmuth C Kolb Journal: J Alzheimers Dis Date: 2013 Impact factor: 4.472
Authors: Kevin F Bieniek; Melissa E Murray; Nicola J Rutherford; Monica Castanedes-Casey; Mariely DeJesus-Hernandez; Amanda M Liesinger; Matthew C Baker; Kevin B Boylan; Rosa Rademakers; Dennis W Dickson Journal: Acta Neuropathol Date: 2012-09-28 Impact factor: 17.088
Authors: Brian A Gordon; Karl Friedrichsen; Matthew Brier; Tyler Blazey; Yi Su; Jon Christensen; Patricia Aldea; Jonathan McConathy; David M Holtzman; Nigel J Cairns; John C Morris; Anne M Fagan; Beau M Ances; Tammie L S Benzinger Journal: Brain Date: 2016-06-10 Impact factor: 13.501
Authors: Jennifer L Whitwell; Stephen D Weigand; Bradley F Boeve; Matthew L Senjem; Jeffrey L Gunter; Mariely DeJesus-Hernandez; Nicola J Rutherford; Matthew Baker; David S Knopman; Zbigniew K Wszolek; Joseph E Parisi; Dennis W Dickson; Ronald C Petersen; Rosa Rademakers; Clifford R Jack; Keith A Josephs Journal: Brain Date: 2012-03 Impact factor: 13.501
Authors: Matthew R Brier; Brian Gordon; Karl Friedrichsen; John McCarthy; Ari Stern; Jon Christensen; Christopher Owen; Patricia Aldea; Yi Su; Jason Hassenstab; Nigel J Cairns; David M Holtzman; Anne M Fagan; John C Morris; Tammie L S Benzinger; Beau M Ances Journal: Sci Transl Med Date: 2016-05-11 Impact factor: 17.956
Authors: Roya Behrouzi; Xiawei Liu; Dongyue Wu; Andrew C Robinson; Sayuri Tanaguchi-Watanabe; Sara Rollinson; Jing Shi; Jinzhou Tian; Hisham H M Hamdalla; John Ealing; Anna Richardson; Matthew Jones; Stuart Pickering-Brown; Yvonne S Davidson; Michael J Strong; Masato Hasegawa; Julie S Snowden; David M A Mann Journal: Acta Neuropathol Commun Date: 2016-03-31 Impact factor: 7.801
Authors: Stacey Li Hi Shing; Mary Clare McKenna; We Fong Siah; Rangariroyashe H Chipika; Orla Hardiman; Peter Bede Journal: Brain Imaging Behav Date: 2021-01-05 Impact factor: 3.978
Authors: Tiziana Petrozziello; Ana C Amaral; Simon Dujardin; Sali M K Farhan; James Chan; Bianca A Trombetta; Pia Kivisäkk; Alexandra N Mills; Evan A Bordt; Spencer E Kim; Patrick M Dooley; Caitlin Commins; Theresa R Connors; Derek H Oakley; Anubrata Ghosal; Teresa Gomez-Isla; Bradley T Hyman; Steven E Arnold; Tara Spires-Jones; Merit E Cudkowicz; James D Berry; Ghazaleh Sadri-Vakili Journal: Brain Pathol Date: 2021-11-14 Impact factor: 6.508